HONG KONG – A deal inked between Carlsbad, Calif.-based Ionis Pharmaceuticals Inc. and Kunshan, China-based Suzhou Ribo Life Science Co. Ltd. will ease the U.S. company's entry into the Chinese innovative drug market, while Ribo picks up a license for two antisense drugs – and an option for a third – aimed at treating metabolic diseases and cancer.